The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended a total of nine new medicines for approval at its April meeting.
The CHMP recommended granting marketing authorisations for two orphan medicines to treat rare neurodegenerative conditions in children. The first, US biotech firm Biogen’s (Nasdaq: BIIB) Spinraza (nusinersen) is to treat patients with spinal muscular atrophy (SMA) It was under an accelerated assessment program. There is currently no approved therapy in the EU for the treatment of spinal muscular atrophy.
The second, from BioMarin Pharmaceuticals (Nasdaq: BMRN), is Brineura (cerliponase alfa) to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease. This was also reviewed under EMA’s accelerated assessment program. There are currently no medicines approved for treatment of CLN2 disease. Current options only treat the symptoms of the disease, a form of Batten disease, which is also known as tripeptidyl peptidase 1 (TPP1) deficiency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze